JULIA MARCHAL: Open Payments
NPI 1235681503 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$547 in 15 payments from 10 companies in 2025. Trend: 2023 $345 · 2024 $604 · 2025 $547
Food & beverage: $547
| Company | Payments | Amount |
|---|---|---|
| TG Therapeutics, Inc. | 1 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Alnylam Pharmaceuticals Inc. | 1 | $77 |
| GENZYME CORPORATION | 3 | $71 |
| Janssen Biotech, Inc. | 2 | $56 |
| Fresenius Kabi USA, LLC | 1 | $33 |
| Janssen Scientific Affairs, LLC | 1 | $25 |
| Alexion Pharmaceuticals, Inc. | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| ARGENX US, INC. | 1 | $21 |
Products named: BRIUMVI, HYQVIA, AMVUTTRA, TREMFYA, NEXVIAZYME, Fabhalta, VYVGART HYTRULO, FABRAZYME.
Industry payments across MI — which companies pay providers there.
